Signaturefd, LLC Vaxcyte, Inc. Transaction History

Signaturefd, LLC

$5.4 Billion
Q2 2025

A detailed history of Signaturefd, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 3,266 shares of PCVX stock, worth $118,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,266

Previous 954 242.35%

Holding current value

$118,359

Previous $36,000 194.44%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 16, 2025	BUY	$28.04 - $37.2 $64,828 - $86,006	2,312 Added 242.35%	3,266 $106,000
Q1 2025 May 01, 2025	SELL	$37.76 - $92.13 $528 - $1,289	-14 Reduced 1.45%	954 $36,000
Q4 2024 Feb 10, 2025	SELL	$80.97 - $117.93 $6,477 - $9,434	-80 Reduced 7.63%	968 $79,000
Q3 2024 Oct 21, 2024	BUY	$70.52 - $117.12 $25,246 - $41,928	358 Added 51.88%	1,048 $119,000
Q2 2024 Jul 29, 2024	SELL	$60.06 - $78.77 $4,624 - $6,065	-77 Reduced 10.04%	690 $52,000
Q1 2024 May 03, 2024	BUY	$59.79 - $81.05 $21,404 - $29,015	358 Added 87.53%	767 $52,000
Q4 2023 Jan 31, 2024	BUY	$45.35 - $63.41 $2,721 - $3,804	60 Added 17.19%	409 $25,000
Q3 2023 Nov 03, 2023	BUY	$46.0 - $53.1 $4,830 - $5,575	105 Added 43.03%	349 $17,000
Q2 2023 Aug 01, 2023	BUY	$34.66 - $54.07 $1,490 - $2,325	43 Added 21.39%	244 $12,000
Q1 2023 Apr 28, 2023	BUY	$36.27 - $47.2 $181 - $236	5 Added 2.55%	201 $7,000
Q4 2022 Jan 27, 2023	BUY	$20.58 - $47.95 $576 - $1,342	28 Added 16.67%	196 $9,000
Q3 2022 Nov 08, 2022	BUY	$21.69 - $28.53 $2,364 - $3,109	109 Added 184.75%	168 $4,000
Q2 2022 Aug 10, 2022	BUY	$17.68 - $26.58 $1,043 - $1,568	59 New	59 $1,000
Q1 2022 May 02, 2022	SELL	$17.46 - $26.36 $157 - $237	-9 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$19.32 - $26.45 $173 - $238	9 New	9 $0

Others Institutions Holding PCVX

# of Institutions

341

Shares Held

136M

Call Options Held

348K

Put Options Held

250K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.15B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account